HSPG2 and neoplasm: Specifically, when utilizing recombinant endorepellin to systemically treat human squamous carcinoma and murine Lewis lung carcinoma in vivo, endorepellin accumulates explicitly in the tumor vasculature, where it markedly suppresses tumor angiogenesis, metabolism, and growth while inducing intratumoral hypoxia (125).